Bond.az - Shares of Ipsen SA (EPA:IPN) fell over 4% despite encouraging mid-stage data for its experimental long-acting neurotoxin corabotase, as investors weighed uncertainty over the drug's commercial strategy and an ongoing arbitration battle with rival Galderma.
Data presented at the Scale Symposium showed 60.8% of patients maintained clinically meaningful reductions in frown-line severity at six months, compared with 36.7% for Dysport and 0.2% for placebo.
UBS analysts, with a "neutral" rating and €170 price target, said the six-month responder rate was "very encouraging" but noted key questions including the impact of shorter-duration products on clinic visits and Ipsen's post-arbitration plans.
Ipsen selected the 50 nanogram dose for Phase III LAURITE trial, with additional data from LANTIC trial expected later this year.
